NSF Awards BioLum Sciences Phase I SBIR Grant for Breath Analysis Device

DALLAS - May 1, 2020 - PRLog -- BioLum Sciences is pleased to announce that the National Science Foundation (NSF) has awarded a $224,808 Phase I SBIR Grant to continue development on a biomedical technology to measure a biomarker of lung inflammation. BioLum's technology would allow for remote monitoring of patients to quickly assess the efficacy of treatment and identify early warning sings of exacerbation to provide an opportunity for intervention and avoid hospitalization. BioLum Sciences will establish a new biomarker testing system with reduced equipment and training requirements, allowing for greater access to breath analysis technology. The purpose of this research is to enhance the repeatability and ease-of-use for BioLum's current breath analysis prototype device. If successful, this research and technology could help improve the management and monitoring of chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disorder (COPD).

"At BioLum Sciences, we want to build an affordable breath analysis device to provide researchers and clinicians broader access to biomarker technology for the ultimate goal of enabling new insights and discoveries in the treatment and management of chronic respiratory diseases." said Miguel Quimbar, co-founder and Principal Investigator for the grant. "As a life-long asthmatic, this project is especially exciting to me because my contributions to the scientific and clinical community could, in the near future, save the lives of other patients like myself."

The Phase I project begins May 1st with chemical and electrical engineering partners, DCN Diagnostics and XWARE Engineering. BioLum Sciences is excited to start this project with the intention of applying for a larger Phase II grant, allowing for further product development and clinical studies.

BioLum Sciences:
The current development pipeline is centered on a point-of-care device and luminescent assays for monitoring respiratory and cardiovascular disease. New assays are being developed simultaneously around our core technology with a vision to accelerate the discovery of new therapies, manage illness, and save lives. The Company recently participated in Bayer Pharmaceutical's G4A Partnerships Program, where the team worked alongside several executives and clinical leads in the pharmaceuticals division. BioLum is currently a resident company at Johnson & Johnson Innovation JLABS @ San Diego, with access to laboratory facilities, equipment, and advisors through the prestigious incubator program. https://www.biolumsciences.com/

The National Science Foundation:
The National Science Foundation (NSF) is an independent federal agency created by Congress in 1950 to promote the progress of science; [and] to advance the national health, prosperity and welfare by supporting research and education in all fields of science and engineering.

Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.